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Purpose: There is controversy surrounding the growth outcomes of treatment with 
gonadotropin-releasing hormone agonist (GnRHa) in central precocious puberty 
(CPP). We analyzed height preservation after treatment with GnRHa with and 
without growth hormone (GH) in girls with CPP. 
Methods: We reviewed the medical records of 82 girls with idiopathic CPP who had 
been treated with GnRHa at Severance Children’s Hospital from 2004 to 2014. We 
assessed the changes in height standard deviation score (SDS) for bone age (BA), 
and compared adult height (AH) with midparental height (MPH) and predicted 
adult height (PAH) during treatment in groups received GnRHa alone (n=59) or 
GnRHa plus GH (n=23). 
Results: In the GnRHa alone group, the height SDS for BA was increased during 
treatment. AH (160.4±4.23 cm) was significantly higher than the initial PAH 
(156.6±3.96 cm) (P<0.001), and it was similar to the MPH (159.9±3.52 cm). In the 
GnRHa plus GH group, the height SDS for BA was also increased during treatment. 
AH (159.3±5.33 cm) was also higher than the initial PAH (154.6±2.55 cm) (P<0.001), 
which was similar to the MPH (158.1±3.31 cm). Height gain was slightly higher 
than that in the GnRHa alone group, however it statistically showed no significant 
correlation with GH treatment. 
Conclusion: In CPP girls treated with GnRHa, the height SDS for BA was increased, 
and the AH was higher than the initial PAH. Combined GH treatment showed a 
limited increase in height gain.
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Introduction
Precocious puberty is defined as the development of secondary sexual characteristics earlier 
than two standard deviations of the mean value1). It occurs at least 10 times more frequently 
in girls than in boys. The clinical manifestations in girls with precocious puberty are breast 
development before 8 years. Public interest in precocious puberty is gradually increasing 
because it can cause psychological discrepancies between physical and chronologic age, 
and it may increase the risks for social problems such as school violence and sexual abuse2). 
Moreover, precocious puberty can cause a shorter final height due to the early closure of the 
epiphyses.
Precocious puberty may be classified into two groups, which are central precocious 
puberty (CPP, also known as true precocious puberty) and peripheral precocious puberty 
(also known as precocious pseudopuberty). CPP is the result of the precocious activation 
of the hypothalamic-pituitary-gonadal axis, and the majority of CPP is idiopathic, which 
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is commonly treated with gonadotropin-releasing hormone 
agonists (GnRHa)3) .
GnRHa is generally considered standard treatment for CPP. It 
reduces gonadotropin release selectively and lowers sex steroid 
hormone secretion to a prepubertal level4). In detail, GnRHa 
acts via desensitization and down-regulation of pituitary GnRH 
receptors and as a result gonadotropin release is gradually 
inhibited after an initial stimulation 'flare-up' phase5). GnRHa 
treatment is reported to be effective in postponing pubertal 
development by slowing the accelerated growth and bone 
maturation, thus preserving height potential3). However, there 
is still controversy over the benefits and effects of GnRHa 
treatment, especially about the preservation of adult height 
(AH)6).
The aim of the present study was to evaluate the statural 
growth outcomes in girls with CPP who were treated with 
GnRHa with or without growth hormone (GH). We analyzed 
height preservation by assessing the changes in height standard 
deviation score (SDS) for bone age (BA), and comparing their 
AHs with their midparental height (MPH) and predicted adult 
height (PAH) prior to GnRHa treatment initiation.  
Materials and methods
1. Subjects
We retrospectively analyzed the medical records of the 82 
girls with idiopathic CPP who were treated with GnRHa and 
attained their final AHs at the Pediatric Endocrinology Clinic of 
Severance Hospital from 2004 to 2014. As some of these patients 
had also received GH treatment, we divided the patients into 
two groups, one group received GnRHa treatment alone (n=59) 
and the other group receiving GnRHa plus GH treatment 
(n=23).
Patients were identified to have idiopathic CPP if  they 
satisfied the classical diagnostic criteria: (1) the onset of breast 
development (Tanner stage B2 or above) before the age of eight, 
(2) peak luteinizing hormone (LH) level of above 5 IU/L in 
the standard intravenous GnRH stimulation test, and (3) no 
evidence of hypothalamic-pituitary organic lesions, confirmed 
by magnetic resonance imaging. Subjects were excluded from 
analysis if they had any additional conditions that could affect 
the onset of puberty such as hypothyroidism or congenital 
adrenal hyperplasia. 
2. Methods
Subcutaneous injections of GnRHa were administered to the 
patients at a dose of 75–150 µg/kg every 28 days. Twenty-eight 
percent of patients (23 of 82 CPP girls) underwent GnRHa and 
GH combined treatment. In the GH combined group, patients 
were treated with subcutaneous injection of GH at a dose of 0.25 
mg/kg per week, 6 days weekly. The GH treatment duration was 
1.9±0.99 years (0.6–4.1 years).
We evaluated height, weight, body mass index (BMI) and BA 
before and after GnRHa treatment. At each evaluation, height 
was measured three times with a Harpenden stadiometer. The 
BA was assessed by the Greulich-Pyle method7) by the same 
observer. Growth parameters such as height, weight, and BMI 
were expressed as SDS, which was calculated using the Korean 
children and adolescents growth standard8). PAH was calculated 
according to the Bayley-Pinneau method9). MPH was defined 
as the average of the parental heights minus 6.5 cm. AH was 
measured at the time when growth velocity was less than 1 cm 
per year, at least two years after menarche, and when BA was 
over 15 years. Also, gain of height SDS (difference between 
AH SDS and initial height SDS for BA), AH–MPH (difference 
values between AH and MPH), and AH–PAH at start (difference 
between AH and initial PAH) were analyzed to assess the 
effectiveness of GnRHa. 
The serum levels of LH, FSH were measured by sequential 
two-step immunoenzymatic assay (Access hLH, FSH Reagent 
Pack, Beckman Coulter Inc., Brea, CA, USA), and E2 level was 
measured using a competitive binding immunoenzymatic assay 
(Access Estradiol Reagent, Beckman Coulter Inc.).
3. Statistical analysis
Statistical analysis of the results was performed using IBM 
SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). All data 
was expressed as mean±standard deviation, and the paired 
t-test was applied to compare the data. Correlations between 
parameters were determined using Pearson correlation coeffi-
cient analysis. A P-value of less than 0.05 was considered 
statistically significant.
Results
1. Auxological characteristics of subjects treated with 
  GnRHa alone during treatment and at AH
Chronological age (CA) and BA at the start of GnRHa treat-
ment were 8.7±0.78 and 10.2±1.60 years, respectively. BA 
was advanced 1.7±0.58 years compared to CA. At the end of 
treatment, BA was 11.9±0.54 years, the difference between BA 
and CA was 1.3±0.63 years, which was lower than the difference 
at the start of treatment (P<0.001) (Table 1). This result suggested 
that GnRHa treatment had an effect on postponing bone 
maturation. Height SDS adjusted for BA was increased during 
treatment and at AH; it was –0.4±0.81 at the start, –0.3±0.80 at 
the end of treatment, and 0.3±0.87 at final (Table 1, Fig. 1). The 
difference values from the start of treatment were 0.1±0.42 at the 
end of treatment (P=0.056), and 0.7±0.82 at AH (P<0.001). This 
result showed that compared to the initial measurements, height 
SDS for BA increased significantly at final AH, whereas it was not 
significantly different during GnRHa treatment. AH (160.4±4.23 
cm) was significantly higher than the initial PAH (156.6±3.96 
cm) (AH–PAH was 3.8±4.03 cm, P<0.001), and similar to MPH 
Jung MK, et al. • Adult height after GnRH agonist and GH in girls with CPP
216 www.e-apem.org
(159.9±3.52 cm) (Table 1. Fig. 2).
2. Auxological characteristics of subjects treated with 
   GnRHa plus GH during treatment and at AH
BA at the start of treatment was 10.5±0.86 years, which 
was 1.7±0.69 years more than CA, whereas BA at the end of 
treatment was 11.9±0.43 years, which was 1.2±0.62 years more 
than CA. The difference between BA and CA at the end of 
treatment was also lower than before treatment, similar to the 
GnRHa alone group (P<0.001) (Table 2). Height SDS for BA 
was also increased during treatment and at AH. It indicated 
–1.0±0.53 before treatment, –0.5±0.82 at the end of treatment, 
and 0.1±1.10 at AH (Table 2, Fig. 1). The difference values from 
the start were 0.5±0.64 at the end of treatment (P<0.001), and 
1.1±1.05 at AH (P<0.001). This result showed that the height SDS 
for BA in the GH combined group constantly increased during 
treatment. AH (159.3±5.33 cm) reached MPH (158.1±3.31 cm), 
and was significantly higher than the initial PAH (154.6±2.55 
cm) (AH–PAH was 4.7±5.04 cm, P<0.001) (Table 2, Fig. 2). 
Table 1. Auxological data in 59 CPP patients treated with GnRHa 
alone during treatment and at adult height
Variable At start of GnRHa At end of GnRHa At adult height
CA (yr) 8.7±0.78 10.6±0.76 15.2±1.53
BA (yr) 10.5±0.86 11.9±0.54 -
BA–CA (yr) 1.7±0.58 1.3±0.63 -
Height (cm) 136.9±7.40 147.4±5.98 160.4±4.23
Weight (kg) 34.3±6.62 43.4±7.31 50.4±5.52
BMI (kg/m2) 18.2±2.36 19.9±2.66 19.6±1.86
Height SDS for CA 1.5±1.09 1.0±0.96a) 0.4±0.80***
Height SDS for BA –0.4±0.81 –0.3±0.80 0.3±0.87***
MPH (cm) - 159.9±3.52 -
PAH (cm) 156.6±3.96 157.1±3.75 -
AH (cm) - - 160.4±4.23
Values are presented as mean±standard deviation. 
CPP, central precocious puberty; GnRHa, gonadotropin-releasing 
hormone agonist; CA, chronological age; BA, bone age; BMI, body 
mass index; SDS, standard deviation score; MPH, midparental 
height; PAH, predicted adult height; AH, adult height.
***P<0.001 vs. start of GnRHa treatment.
Table 2. Auxological data in 23 CPP patients treated with GnRHa 
plus GH during treatment and at adult height
Variable At start of GnRHa At end of GnRHa At adult height
CA (yr) 8.8±0.59 10.8±0.51 15.4±1.23
BA (yr) 10.5±0.86 11.9±0.43 -
BA–CA (yr) 1.7±0.69 1.2±0.62 -
Height (cm) 133.8±5.47 146.6±5.62 159.3±5.33
Weight (kg) 31.2±4.70 39.7±6.31 47.8±6.07
BMI (kg/m2) 17.3±1.55 18.4±2.00 18.0±4.27
Height SDS for CA 0.7±0.84 0.8±0.88 0.0±1.03***
Height SDS for BA –1.0±0.53 –0.5±0.82a) 0.1±1.10***
MPH (cm) - 158.1±3.31 -
PAH (cm) 154.6±2.55 156.0±3.82 -
AH (cm) - - 159.3±5.33
Values are presented as mean±standard deviation. 
CPP, central precocious puberty; GnRHa, gonadotropin-releasing 
hormone agonist; GH, growth hormone; CA, chronological age; 
BA, bone age; BMI, body mass index; SDS, standard deviation 
score; MPH, midparental height; PAH, predicted adult height; AH, 
adult height.
***P<0.001 vs. start of GnRHa treatment.
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Fig. 1. Changes in height standard deviation score (SDS) for bone age (BA) 
during treatment in 59 central precocious puberty (CPP) patients treated 
with gonadotropin-releasing hormone agonist (GnRHa) alone (◆) and in 23 
CPP patients treated with GnRHa plus GH (■). AH, adult height; GH, growth 
hormone.***P<0.001 vs. start of GnRHa treatment. 
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Fig. 2. Initial predicted height, midpatental height and ault height of 59 central 
precocious puberty (CPP) patients treated with gonadotropin-releasing hormone 
agonist (GnRHa) alone and in 23 CPP patients treated with GnRHa plus growth 
hormone (GH). PAH, predicted adult height; AH, adult height; MPH, midparental 
height. ***P<0.001 vs. initial PAH. 
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3. Comparison of growth outcomes between 
   GnRHa alone group and GnRHa plus GH group
Gain of height SDS (difference between AH SDS and initial 
height SDS for BA) were 1.0±0.91 in GnRHa alone group and 
1.2±0.93 in GnRHa plus GH group, showing no significant 
difference between the two groups (P=0.44) (Table 3). It could 
be explained that the height gain was slightly higher in the GH 
combined group, but it was not to be a statistically significant 
level. In addition, AM-MPH (0.5±4.11 cm in GnRHa alone vs. 
1.2±5.47 cm in the GH combined group, P=0.53) and AH-PAH 
at start (3.8±4.03 cm in GnRHa alone vs. 4.7±5.06 cm in the GH 
combined group, P=0.43) presented no significant difference 
between two groups (Table 3). 
4. The correlation between AH and other auxological factors 
Multiple regression analysis was done to find the factors 
to influence the growth outcomes on AH SDS (Table 4). The 
GH combined group was excluded, since GH could be a 
compounding factor. The AH SDS showed statistically positive 
effects when the CA at start was younger, MPH was taller. The 
BA at start, BA–CA at start, PAH at start, height SDS at start, 
and duration of treatment had no correlation with the growth 
outcome. 
5. Time of menarche and growth pattern after cessation of 
    GnRHa
The time of menarche and the growth pattern after cessation 
of GnRHa treatment were analyzed (Table 5). Duration from 
cessation of GnRHa to menarche was 1.0±0.61 years. Height 
increment from cessation of GnRHa to menarche was 5.9±3.65 
cm, whereas the height increment after menarche was 7.1±2.25 
cm. Thus, height increment from cessation of GnRHa to final 
AH was 13.0±4.31 cm. 
Discussion
The timing of normal puberty has shown a dramatic decline 
in age during past centuries. Moreover, the number of patients 
with CPP has been significantly increased recently. This trend 
also occurred in Korea with a four- to five-fold increase of CPP 
in girls over the last five years10). CPP may cause physical and 
psychological problems for affected girls, so some girls with CPP 
could be at risk of premature sexual activity, and consequently, 
sexual abuse. Some reports have shown increased behavioral 
disturbances, including drug abuse and low socio-culture 
outcomes11). Therefore, proper treatment for CPP is important, 
not only for individuals but also for society.  
GnRHa is generally accepted as the treatment of choice for 
the improvement of final AH preservation and also for the 
reduction of psychosocial problems in CPP patients, however 
controversy still exists over whether GnRHa treatment 
improves final AH. Lazar et al.12) found that GnRHa treatment 
results in little or no increase in final AH when treatment is 
initiated after eight years of age. In a study by Pasquino et al.13) 
in which 87 GnRHa-treated (age, 6.5 years) and 32 nontreated 
girls with idiopathic CPP (age, 6.8 years), the final AH of treated 
and nontreated girls were 159.8 and 154.4 cm, respectively. 
Heger et al.14) also reported on 50 girls with precocious puberty 
undergoing GnRHa treatment for two years, whose final AH 
averaged 160.6±8.0 cm (–0.6±1.3 SDS), which was significantly 
Table 3. Outcome results at final height of the CPP patients 
treated with GnRHa alone and GnRHa plus GH
Outcome GnRHa alone(n=59)
GnRHa plus GH 
(n=23) P-value
MPH (cm) 159.9±3.52 158.1±3.31 0.03
PAH at start (cm) 156.6±3.96 154.6±2.55 0.03
AH (cm) 160.4±4.23 159.3±5.33 0.34
AH SDS 0.4±0.80     0.0±1.02 0.34
Gain of height SDS 1.0±0.91     1.2±0.93 0.44
AH–MPH (cm) 0.5±4.11     1.2±5.47 0.53
AH–PAH at start (cm) 3.8±4.03     4.7±5.06 0.43
Values are presented as mean±standard deviation. 
CPP, central precocious puberty; GnRHa, gonadotropin-releasing 
hormone agonist; GH, growth hormone; MPH, midparental 
height; PAH, predicted adult height; AH, adult height; SDS, 
standard deviation score; AH–MPH, difference between AH and 
MPH; AH–PAH at start, difference between AH and initial PAH.
Table 4. Multiple regression analysis on AH SDS
Variable Regression coefficient SE P-value
CA at start (yr) –0.43 0.17 0.01
BA at start (yr) 0.09 0.07 0.21
BA–CA at start (yr) –0.15 0.31 0.62
MPH (cm) 0.05 0.03 0.05
PAH at start (cm) 0.03 0.13 0.83
Height SDS for CA at start 0.25 0.21 0.24
Height SDS for BA at start –0.02 0.74 0.98
Duration of treatment (mo) –0.12 0.16 0.45
AH, adult height; SDS, standard deviation score; SE, standard 
error; CA, chronological age; BA, bone age; MPH, midparental 
height; PAH, predicted adult height.
Table 5. Time of menarche and height increment after cessation 
of GnRHa
Variable Mean±SD (range)
CA at end of GnRHa (yr) 10.7±0.70 (8.0–12.1)
BA at end of GnRHa (yr) 11.9±0.51 (9.0–12.8)
CA at menarche (yr) 11.6±0.90 (9.5–13.2)
BA at menarche (yr)   12.6±0.59 (11.0–14.0)
Duration from cessation of GnRHa to 
  menarche (yr)
1.0±0.61 (0.0–2.4)
Height increment from cessation of GnRHa to
  menarche (cm)
  5.9±3.65 (0.0–14.3)
Height increment after menarche (cm) 7.1±2.25 (1.0–9.0)
GnRHa, gonadotropin-releasing hormone agonist ;  CA, 
chronological age; BA, bone age. 
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higher than the initial PAH of 154.9±9.6 cm. Our 82 GnRHa-
treated CPP girls achieved final heights that were significantly 
greater than their pretreatment PAH, which is in agreement 
with recent studies. In our study, height gain was approximately 
3.8 cm in the GnRHa alone group, while 4.7 cm in the GH plus 
group. In addition, AH showed a taller tendency when the CA at 
start was younger and MPH was taller. 
Another issue of this study is whether combined GH treat-
ment improves the growth outcomes of CPP girls. There 
have been few previous studies about the effectiveness of GH 
combined therapy on growth outcomes. Pasquino et al.15) and 
Pucarelli et al.16) showed differences of about 6–8 cm of height 
gain on girls with CPP treated with GnRHa plus GH were 
noted, compared to GnRHa alone. Until the present, there have 
been no definite conclusions about the growth outcomes of 
GH-combined treatments. In this study, gain of height SDS and 
difference between AH and initial PAH were slightly higher 
in the GnRHa plus GH group than in the GnRHa alone group 
in CPP girls, however it showed no statistically significant 
difference between two groups. These results suggested that 
combined GH treatment showed a limited increase in height 
gain. Growth pattern between two groups showed that height 
SDS for BA was continuously increased during treatment and 
at AH in the GnRHa plus GH group, whereas it was increased 
only at AH in the GnRHa alone group. This result may result 
from several reasons. One possibility is that the choice of GH 
treatment might have a selection bias. Those who have low 
height potential or attenuated growth velocity might tend to 
choose the combined GH treatment. Because GH treatment 
requires the consideration of cost, economic status may be 
another affecting factor to select the patients treated with 
GnRHa plus GH. Furthermore, GH treatment duration could 
be another influencing factor. Cost-effectiveness of combined 
GH treatment in patients with CPP has to be elucidated. 
The suppression of the hypothalamic-pituitary-gonadal 
axis was fully recovered after discontinuation of GnRHa. The 
average time span from the cessation of treatment to menarche 
was 1.0 years. Our data about the growth pattern after cessation 
of GnRHa can be helpful to predict the height increase after 
discontinuation of  GnRHa. In addition, there have been 
conflicting data regarding the increase in obesity during GnRHa 
treatment17). In present study, the BMI score of girls treated with 
GnRHa was not significantly increased during treatment. In 
addition, no adverse effects have been observed. 
There were some limitations in our study. GnRHa treatment 
is not an only single factor to determine the growth outcomes, 
rather the effects of nutrition, psychosocial status, genetic height 
potential, and others may influence the outcome. Because 
GnRHa has recently been accepted as the standard therapy for 
CPP, GnRHa-untreated patients could not be enrolled in this 
study. Furthermore, it is considered that further studies about 
the growth outcomes in CPP girls treated with GnRHa plus GH 
are required.
In this study about GnRHa treatment in CPP girls, the final 
AH was significantly higher than the initial height predictions 
and was close to the MPH. Therefore, it can be concluded that 
GnRHa treatment is helpful to improve the growth outcomes in 
girls with CPP.
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